Pasithea Therapeutics Corp. (KTTA): Cash & Equivalents
$55.16M
As of 2025-12-31
$45.66M
As of 2026-06-30
+18.6%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $55.16M | +696.8% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $6.92M | -57.6% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $16.33M | -50.6% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $33.09M | -37.5% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $52.97M | n/m | 2023-03-30, Balance as of period end |
| 2020-12-31 | $243.7K | n/a | 2022-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $55.16M | +696.8% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $90.0K | -86.7% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $57.98M | -30.6% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $15.65M | +417.3% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $16.37M | -6.8% |
| Scynexis Inc (SCYX) | 2025-12-31 | $21.26M | +32.4% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $48.30M | -38.1% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $18.62M | +394.9% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $19.94M | -6.6% |
Compare KTTA, PRPH, PVLA, DMAC side by side · Screen every company in Pharmaceutical Preparations ↗